Ginkgo Bioworks Wins $22.2 Million BARDA Contract for Anti-Filovirus Antibody Production

Reuters

11/03

<a href="https://laohu8.com/S/DNA.WS">Ginkgo Bioworks</a> Wins $22.2 Million BARDA Contract for Anti-Filovirus Antibody Production

Ginkgo Bioworks Holdings Inc. announced that it has been awarded a contract valued at up to $22.2 million through the Biomedical Advanced Research and Development Authority's (BARDA) Biopharmaceutical Manufacturing Preparedness Consortium (BioMaP-Consortium). The project aims to develop innovations to strengthen and reduce the costs of domestic biomanufacturing of monoclonal antibodies for protection against and treatment of infections caused by filoviruses such as Ebola and Sudan viruses. The initiative will focus on producing an anti-filovirus monoclonal antibody cocktail, 1C3 and 1C11, originally developed by Emory University. Ginkgo Bioworks will collaborate with partners including ABL, Isolere Bio by Donaldson, NeuImmune, and ProteoNic to advance biomanufacturing technologies as part of this federally funded project.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Ginkgo Bioworks Holdings Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: NE11791) on November 03, 2025, and is solely responsible for the information contained therein.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2580562213"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2580562213\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2580562213?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-03 21:02","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2580562213","market":"us","top_or_hot":-1,"title":"Ginkgo Bioworks Wins $22.2 Million BARDA Contract for Anti-Filovirus Antibody Production","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/DNA.WS\">Ginkgo Bioworks</a> Wins $22.2 Million BARDA Contract for Anti-Filovirus Antibody Production\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/DNA\">Ginkgo Bioworks Holdings Inc.</a> announced that it has been awarded a contract valued at up to $22.2 million through the Biomedical Advanced Research and Development Authority's (BARDA) Biopharmaceutical Manufacturing Preparedness Consortium (BioMaP-Consortium). The project aims to develop innovations to strengthen and reduce the costs of domestic biomanufacturing of monoclonal antibodies for protection against and treatment of infections caused by filoviruses such as Ebola and Sudan viruses. The initiative will focus on producing an anti-filovirus monoclonal antibody cocktail, 1C3 and 1C11, originally developed by Emory University. Ginkgo Bioworks will collaborate with partners including ABL, Isolere Bio by Donaldson, NeuImmune, and ProteoNic to advance biomanufacturing technologies as part of this federally funded project.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. <a href=\"https://laohu8.com/S/DNABW\">Ginkgo Bioworks Holdings Inc.</a> published the original content used to generate this news brief via PR Newswire (Ref. ID: NE11791) on November 03, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Ginkgo Bioworks Wins $22.2 Million BARDA Contract for Anti-Filovirus Antibody Production</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nGinkgo Bioworks Wins $22.2 Million BARDA Contract for Anti-Filovirus Antibody Production\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time smaller\">2025-11-03 21:02</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/DNA.WS\">Ginkgo Bioworks</a> Wins $22.2 Million BARDA Contract for Anti-Filovirus Antibody Production\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/DNA\">Ginkgo Bioworks Holdings Inc.</a> announced that it has been awarded a contract valued at up to $22.2 million through the Biomedical Advanced Research and Development Authority's (BARDA) Biopharmaceutical Manufacturing Preparedness Consortium (BioMaP-Consortium). The project aims to develop innovations to strengthen and reduce the costs of domestic biomanufacturing of monoclonal antibodies for protection against and treatment of infections caused by filoviruses such as Ebola and Sudan viruses. The initiative will focus on producing an anti-filovirus monoclonal antibody cocktail, 1C3 and 1C11, originally developed by Emory University. Ginkgo Bioworks will collaborate with partners including ABL, Isolere Bio by Donaldson, NeuImmune, and ProteoNic to advance biomanufacturing technologies as part of this federally funded project.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. <a href=\"https://laohu8.com/S/DNABW\">Ginkgo Bioworks Holdings Inc.</a> published the original content used to generate this news brief via PR Newswire (Ref. ID: NE11791) on November 03, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"DNA","symbol_name":"Ginkgo Bioworks Holdings Inc.","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251103:nNDL2qFrhF:1","article_id":"2580562213","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2580562213","pubTimestamp":1762174979,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Ginkgo Bioworks Holdings Inc. announced that it has been awarded a contract valued at up to $22.2 million through the Biomedical Advanced Research and Development Authority's  Biopharmaceutical Manufacturing Preparedness Consortium . The project aims to develop innovations to strengthen and reduce the costs of domestic biomanufacturing of monoclonal antibodies for protection against and treatment of infections caused by filoviruses such as Ebola and Sudan viruses. The initiative will focus on producing an anti-filovirus monoclonal antibody cocktail, 1C3 and 1C11, originally developed by Emory University. Ginkgo Bioworks will collaborate with partners including ABL, Isolere Bio by Donaldson, NeuImmune, and ProteoNic to advance biomanufacturing technologies as part of this federally funded project.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated conten","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"DNA":"Ginkgo Bioworks Holdings Inc.","BK4161":"工业机械","BK4139":"生物科技","BK4121":"生命科学工具和服务","DCI":"唐纳森","BK4109":"特种化学制品"},"translate_title":"Ginkgo Bioworks赢得价值2220万美元的BARDA抗丝状病毒抗体生产合同","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"DCI":0.9,"DNA":0.9},"content_text":"Ginkgo Bioworks Wins $22.2 Million BARDA Contract for Anti-Filovirus Antibody Production\n    \n\nGinkgo Bioworks Holdings Inc. announced that it has been awarded a contract valued at up to $22.2 million through the Biomedical Advanced Research and Development Authority's (BARDA) Biopharmaceutical Manufacturing Preparedness Consortium (BioMaP-Consortium). The project aims to develop innovations to strengthen and reduce the costs of domestic biomanufacturing of monoclonal antibodies for protection against and treatment of infections caused by filoviruses such as Ebola and Sudan viruses. The initiative will focus on producing an anti-filovirus monoclonal antibody cocktail, 1C3 and 1C11, originally developed by Emory University. Ginkgo Bioworks will collaborate with partners including ABL, Isolere Bio by Donaldson, NeuImmune, and ProteoNic to advance biomanufacturing technologies as part of this federally funded project.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Ginkgo Bioworks Holdings Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: NE11791) on November 03, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}